Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;32(10):e218.
doi: 10.1016/j.clon.2020.06.001. Epub 2020 Jun 9.

Adjuvant Systemic Anti-cancer Therapy in Early Breast Cancer During the COVID-19 Pandemic: Differences between Clinicians and Patients in Perception of Treatment Risks and Benefits

E R Gatfield  1 , M B Mukesh  1 , S W Loo  1
Affiliations

Adjuvant Systemic Anti-cancer Therapy in Early Breast Cancer During the COVID-19 Pandemic: Differences between Clinicians and Patients in Perception of Treatment Risks and Benefits

E R Gatfield et al. Clin Oncol (R Coll Radiol). 2020 Oct.
No abstract available

PubMed Disclaimer

References

    1. Zhang L., Zhu F., Xie L., Wang C., Wang J., Chen R., et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020 doi: 10.1016/j.annonc.2020.03.296. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence . 2020. Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England.https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-chang... Available at:
    1. Earl H.M., Hiller L., Vallier A.L., Shrushma L., McAdam K., Hughes-Davies L., et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599–2612. - PMC - PubMed